» Articles » PMID: 32228244

Cysteine Cathepsins As Therapeutic Targets in Inflammatory Diseases

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2020 Apr 2
PMID 32228244
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

: Cysteine cathepsins are involved in the development and progression of numerous inflammation-associated diseases such as cancer, arthritis, bone and immune disorders. Consequently, there is a drive to progress research efforts focused on cathepsin use in diagnostics and as therapeutic targets in disease.: This review discusses the potential of cysteine cathepsins as therapeutic targets in inflammation-associated diseases and recent advances in preclinical and clinical research. We describe direct targeting of cathepsins for treatment purposes and their indirect use in diagnostics.: The targeting of cysteine cathepsins has not translated into the clinic; this failure is attributed to off- and on-target side effects and/or the lack of companion biomarkers. This field now embraces developments in diagnostic imaging, the activation of prodrugs and antibody-drug conjugates for targeted drug delivery. The future lies in improved molecular tools and therapeutic concepts that will find a wide spectrum of uses in diagnostic and therapeutic applications.

Citing Articles

Causal relationship between cathepsins and major salivary gland neoplasms: a bidirectional Mendelian randomization study.

Zhuang S, Ding H, Huang H, Wang T, Li C, Zeng X Gland Surg. 2024; 13(11):2148-2162.

PMID: 39678421 PMC: 11635577. DOI: 10.21037/gs-24-374.


Cysteine cathepsins and autoimmune diseases: A bidirectional Mendelian randomization.

Wu Y, Li Q, Lou Y, Zhou Z, Huang J Medicine (Baltimore). 2024; 103(43):e40268.

PMID: 39470488 PMC: 11521024. DOI: 10.1097/MD.0000000000040268.


Advances in Cathepsin S Inhibition: Challenges and Breakthroughs in Drug Development.

Ajani T, Magwebu Z, Chauke C, Obikeze K Pathophysiology. 2024; 31(3):471-487.

PMID: 39311309 PMC: 11417842. DOI: 10.3390/pathophysiology31030035.


Decreased Cathepsin-K Mirrors the Severity of Subclinical Atherosclerosis in Kidney Transplant Recipients.

Bolignano D, Greco M, Arcidiacono V, Presta P, Caglioti A, Russo E Rev Cardiovasc Med. 2024; 23(9):311.

PMID: 39077719 PMC: 11262360. DOI: 10.31083/j.rcm2309311.


Discovering novel Cathepsin L inhibitors from natural products using artificial intelligence.

Li Q, Zhou S, Kim H, Wang H, Zhu J, Yang J Comput Struct Biotechnol J. 2024; 23:2606-2614.

PMID: 39006920 PMC: 11245987. DOI: 10.1016/j.csbj.2024.06.009.